November 12th, 2026Oral Enlicitide Could Close Primary Prevention Gap: Christie Ballantyne, MDIn this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.Read more
November 12th, 2026Shifting From Late Rescue to Early COPD Detection and CareExperts at GOLD 2026 say targeted case finding, AI, and guideline-based treatment can close COPD’s diagnostic gap and improve patient outcomes.Read more
November 12th, 2026The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH CostsPhase 3 hepatitis delta data, MASH persistence and cost findings, and new PBC treatment targets led The Liver Meeting 2026 in Denver, Colorado.Read more
November 11th, 2026Shorter Telomeres Tied to UIP Pattern, Not Fibrosis Extent, in ILDShorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.Read more
November 11th, 2026AI Is a Copilot, Not a Decision Maker, Oncology Panel SaysOncology leaders discuss where AI delivers value, who bears liability, data readiness, and why humans must stay in the loop for clinical decisions.Read more
November 9th, 2026Phase 3 Data Back ALP Normalization as Treatment Goal in PBCElafibranor and seladelpar normalized ALP in most patients with primary biliary cholangitis whose ALP was below the usual escalation threshold. Read more
November 9th, 2026Pharmacy, Claims Data Show High Resmetirom Persistence in MASHMost patients with MASH stay on resmetirom at 1 year, but Medicaid coverage was tied to lower odds of filling a first prescription within 30 days. Read more
November 9th, 2026Two Decades of Immunotherapy Reshaped Lung Cancer TreatmentA 20-year review traces how immune checkpoint inhibitors became a cornerstone of lung cancer treatment.Read more